Search
Pecavaptan
go.drugbank.com/drugs/DB16279InvestigationalPecavaptan is under investigation in clinical trial NCT03901729 (A Trial to Study BAY1753011 in Patients With Congestive Heart Failure).
Praliciguat
go.drugbank.com/drugs/DB16300InvestigationalPraliciguat is under investigation in clinical trial NCT03254485 (A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (Hfpef)).
GSK-2981278
go.drugbank.com/drugs/DB16319InvestigationalGSK-2981278 is under investigation in clinical trial NCT03004846 (A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis).
Seviprotimut-L
go.drugbank.com/drugs/DB16328InvestigationalSeviprotimut-L is under investigation in clinical trial NCT01546571 (Study of a Melanoma Vaccine in Stage Iib, Iic, and III Melanoma Patients).
Vixarelimab
go.drugbank.com/drugs/DB16350InvestigationalVixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis).
Vonlerolizumab
go.drugbank.com/drugs/DB16352InvestigationalVonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic
Matrix-M
go.drugbank.com/drugs/DB16369InvestigationalMatrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax.
Astegolimab
go.drugbank.com/drugs/DB16386InvestigationalAstegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
Pidacmeran
go.drugbank.com/drugs/DB16401InvestigationalPidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
V590
go.drugbank.com/drugs/DB16437ExperimentalBy teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose[L30583]. … Other features of this vaccine include potential activity with oral administration _via_ a swish-and-swallow protocol[L30583].